Navigation Links
VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting
Date:4/20/2009

FMT(TM) Quantitative Tomographic Imaging Being Expanded to Four Fluorescent Channels to Enable Greater Data Ranges and Multiplexing of Disease Biomarkers In Vivo

VisEn Multi-Modality Imaging Adapter Series Launched to Enable Imaging, Co-Registration and Data Fusion Between FMT and CT, MR, Spect and PET

BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced that users of its FMT 2500 Quantitative Tomography Platform will soon be able to access four channels of quantitative fluorescent imaging -- 635 nm, 670 nm, 745 nm, and 790 nm -- allowing greater flexibility in imaging and multiplexing of VisEn's fluorescent imaging agents in multiple disease pathways in vivo. VisEn also announced today that it has launched its proprietary line of FMT Multi-Modality Adaptors designed to enable researchers to readily combine FMT readouts with imaging results from complementary microCT, PET, MR and Spect platforms. The announcements were made during the AACR (American Association of Cancer Research) 100th Annual Meeting 2009, being held April 18-22, 2009 in Denver, CO.

FMT 2500 Four Channel Imaging Upgrade and System Available Summer 2009

The expanded FMT 2500 Four Channel offering will become available in the summer of 2009 and can be purchased as an upgrade to existing FMT 2500 systems, or as an added feature to a new FMT system. In addition to the standard wavelengths of 670 nm and 745 nm offered in the FMT 2500, VisEn will now offer customers FMT imaging in two new laser wavelengths: 635 nm and 790 nm. Upgrading the FMT 2500 from two to four channels to span a broader spectral fluorescence range from 650 - 850 nm allows researchers greater imaging and fluorescence quantification capability in vivo.

"This expanded range of multi-modality and multi-plexing in vivo imaging products will allow FMT 2500-equipped research and pharmaceutical scientists even greater capabilities in measuring and quantifying biomarkers, disease progression and therapeutic efficacy in vivo," said Kirtland Poss, President and CEO of VisEn. "We could not be more pleased with how these technologies continue to expand translational research and drug development today."

FMT 2500 Multi-Modality Adaptors Available Now

VisEn's new line of FMT Multi-Modality imaging adapters enables research scientists to combine imaging approaches and to fuse data sets from both FMT and a second modality including MRI, CT, Spect or PET. This resulting integration of quantified FMT biomarker readouts with precise anatomic morphology provides users the unprecedented ability to measure and monitor disease pathways and therapeutic efficacy in vivo. Examples can been seen at: www.visenmedical.com/applications/multi-modality_imaging/index.html.

Four models are now available and allow for multi-modality imaging between FMT and each of the following modalities: Siemens Inveon(TM) (mu)PET/CT, Gamma Medica's (mu)CT, Bruker's (mu)MRI and GE's (mu)CT.

The FMT 2500 is based upon VisEn's proprietary Fluorescence Molecular Tomography (FMT) technology platform which enables researchers to rapidly and easily generate in vivo quantitative tomographic data by using three key steps: data generation, data normalization, and fluorescence tomographic reconstruction. The researcher is therefore able to quantify biological targets and fluorescent agents to the picomole in vivo and in real time. The system offers multiplexed imaging capabilities so users can measure, monitor, and compare multiple in vivo biologic targets, pathways or processes simultaneously using different fluorescence agents.

Find out more about both the expanded Four Channel FMT 2500 System and the Multi-Modality Adaptors at VisEn's Booth #451 at AACR 2009 in Denver, at Booth #407 at Experimental Biology (EB) in New Orleans, or at www.visenmedical.com.

About VisEn Medical

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT(TM)) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. OBS Medicals Visensia Patient Monitoring Technology Lowers Cost of Medical Malpractice Insurance
2. CRi to Distribute VisEn Medicals Portfolio of Fluorescence In Vivo Imaging Agents and Labels in North America
3. VisEn Co-Founder Named Radiologic Societys Outstanding Researcher of the Year
4. VisEn Medical Raises $5.0 Million in Expanded Series B Financing
5. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
6. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
7. Spring Lineup of Medical Spa Webinars for MedSpa Professionals by Acara
8. Matrixmj.Com Revolutionizing The Way Medical Professionals Seek And Find Employment; Job Board Debuts Innovative Method For Matching Healthcare Candidates And Job Opportunties
9. reThinking eHealth Webinar: Will the Patient Centered Medical Home Be the Model for Universal Healthcare?
10. Medical EMR Software To Be Subdized In Pres. Obama's Economic Stimulus Plan - Lives Can Be Saved As A Result
11. Veteran Medical Malpractice Litigator Gary S. Genovese Re-Joins Conrad & Scherer LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... Researchers can ... so routine. A fresh look at this technique may yield big benefits. Scientists ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of contamination ...
(Date:5/23/2016)... ... May 23, 2016 , ... In light of ... reminds pet owners that intervening at the first sign of their pet overheating ... normal body mechanisms cannot keep the body’s temperature within a safe range. Considered ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... ... 2016 , ... Hadley Institute for the Blind and Visually ... or visually impaired, announces the election of Julie S. Tye as its next ... of Trustees retained Morris & Berger, a firm specializing in non-profit executive searches, ...
(Date:5/23/2016)... NY (PRWEB) , ... May 23, 2016 , ... ... the company’s top management team to meet the needs of its recent and ... to drive continued growth and business development across widening market segments. Max joined ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
Breaking Medicine Technology: